Glecirasib monotherapy demonstrated efficacy in previously treated patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC) according to data presented during the ASCO Plenary Series: April 2024 Session (Abstract 468214).
Question 1 of 5
What was the objective response rate associated with glecirasib, an oral inhibitor of KRAS G12C, in a pivotal phase II study which included previously treated patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC)?
